The effectiveness of Suanzaoren in treating insomnia among patients with anxiety: a multicentre randomized trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019913

Enrollment

Unknown

Registered

2018-12-08

Start date

2018-02-25

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety

Interventions

Experimental group:Zaoren Anshen capsule and conventional treatment

Control group:Conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-65 years old; 2. Hamilton Anxiety Rating Scale (HAM-A) score >= 17; 3. insomnia severity index >=14; 4. on Alprazolam medication; 5. able to sign the consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with abnormal liver and kidney function; 2. have taken other medication for treatment of insomnia; 3. patients who are allergic to treatment drugs; 4. HAMA, ISI does not meet the inclusion criteria; 5. patients with severe mental illness; 6. unstable cardiovascular and cerebrovascular diseases; 7. The investigator believes that it does not meet other reasons for participation.

Design outcomes

Primary

Measure	Time frame
Insomnia Severity Index;	—

Secondary

Measure	Time frame
Hamilton Anxiety Rating Scale;Pittsburgh Sleep Quality Index;	—

Countries

China

Contacts

Public ContactZhang Hai-Xiao

Hangzhou Rad Cross Hospital

281112509@qq.com+86 15918099905

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026